Stock Track | Takeda Pharmaceutical Plummets 5.01% After Reporting Lower Q4 Earnings

Stock Track

May 08, 2025

Shares of Takeda Pharmaceutical Co Ltd (TAK) plummeted 5.01% in pre-market trading on Thursday following the release of its fiscal fourth-quarter earnings report, which showed a significant decline in core earnings.

The Japanese pharmaceutical giant reported quarterly earnings of $0.16 per share, marking a substantial 33.33% decrease from $0.24 per share in the same period last year. Sales also saw a slight dip, coming in at $7.02 billion for the quarter, down 0.93% from $7.08 billion in the previous year.

The disappointing earnings report comes amid a broader downturn in the healthcare sector. The Health Care Select Sector SPDR Fund (XLV) was down 0.9% pre-market, while the iShares Biotechnology ETF (IBB) declined 0.7%. Takeda's performance, however, stood out with its more pronounced drop, reflecting investors' concerns about the company's financial health and growth prospects in a challenging market environment.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1109491881"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1109491881\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1109491881?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-08 22:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1109491881","market":"us","top_or_hot":-1,"title":"Stock Track | Takeda Pharmaceutical Plummets 5.01% After Reporting Lower Q4 Earnings","media":"Stock Track","content":"<p>Shares of Takeda Pharmaceutical Co Ltd (TAK) plummeted 5.01% in pre-market trading on Thursday following the release of its fiscal fourth-quarter earnings report, which showed a significant decline in core earnings.</p>\n\n<p>The Japanese pharmaceutical giant reported quarterly earnings of $0.16 per share, marking a substantial 33.33% decrease from $0.24 per share in the same period last year. Sales also saw a slight dip, coming in at $7.02 billion for the quarter, down 0.93% from $7.08 billion in the previous year.</p>\n\n<p>The disappointing earnings report comes amid a broader downturn in the healthcare sector. The Health Care Select Sector SPDR Fund (XLV) was down 0.9% pre-market, while the iShares Biotechnology ETF (IBB) declined 0.7%. Takeda's performance, however, stood out with its more pronounced drop, reflecting investors' concerns about the company's financial health and growth prospects in a challenging market environment.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Takeda Pharmaceutical Plummets 5.01% After Reporting Lower Q4 Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Takeda Pharmaceutical Plummets 5.01% After Reporting Lower Q4 Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-05-08 22:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Takeda Pharmaceutical Co Ltd (TAK) plummeted 5.01% in pre-market trading on Thursday following the release of its fiscal fourth-quarter earnings report, which showed a significant decline in core earnings.</p>\n\n<p>The Japanese pharmaceutical giant reported quarterly earnings of $0.16 per share, marking a substantial 33.33% decrease from $0.24 per share in the same period last year. Sales also saw a slight dip, coming in at $7.02 billion for the quarter, down 0.93% from $7.08 billion in the previous year.</p>\n\n<p>The disappointing earnings report comes amid a broader downturn in the healthcare sector. The Health Care Select Sector SPDR Fund (XLV) was down 0.9% pre-market, while the iShares Biotechnology ETF (IBB) declined 0.7%. Takeda's performance, however, stood out with its more pronounced drop, reflecting investors' concerns about the company's financial health and growth prospects in a challenging market environment.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TAK","symbol_name":"武田制药","start_time":0,"source_url":"","article_id":"1109491881","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1109491881","pubTimestamp":1746714957,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Takeda Pharmaceutical Co Ltd  plummeted 5.01% in pre-market trading on Thursday following the release of its fiscal fourth-quarter earnings report, which showed a significant decline in core earnings.The Japanese pharmaceutical giant reported quarterly earnings of $0.16 per share, marking a substantial 33.33% decrease from $0.24 per share in the same period last year. Sales also saw a slight dip, coming in at $7.02 billion for the quarter, down 0.93% from $7.08 billion in the previous ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TAK":"武田制药"},"translate_title":"武田制药第四季度盈利下降后暴跌5.01%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TAK":1},"content_text":"Shares of Takeda Pharmaceutical Co Ltd (TAK) plummeted 5.01% in pre-market trading on Thursday following the release of its fiscal fourth-quarter earnings report, which showed a significant decline in core earnings.\nThe Japanese pharmaceutical giant reported quarterly earnings of $0.16 per share, marking a substantial 33.33% decrease from $0.24 per share in the same period last year. Sales also saw a slight dip, coming in at $7.02 billion for the quarter, down 0.93% from $7.08 billion in the previous year.\nThe disappointing earnings report comes amid a broader downturn in the healthcare sector. The Health Care Select Sector SPDR Fund (XLV) was down 0.9% pre-market, while the iShares Biotechnology ETF (IBB) declined 0.7%. Takeda's performance, however, stood out with its more pronounced drop, reflecting investors' concerns about the company's financial health and growth prospects in a challenging market environment.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}